What the Evidence Really Shows for Hair Growth Ingredients and Claims

Minoxidil remains the ingredient with the strongest evidence: a 2026 systematic review with network meta-analyses in the journal Medicina analyzed 23 studies and ranked topical minoxidil 5% most effective for male pattern hair loss. A Frontiers in Pharmacology review from Melbourne's SinclairDermatology notes topical minoxidil is the only FDA-approved option for this hair loss in both sexes.

What does the evidence actually show for minoxidil?

The 2026 network meta-analysis by Aditya Gupta and colleagues searched PubMed, Scopus, Web of Science, and ClinicalTrials.gov through January 2026 and compared off-label and unregulated therapies against topical minoxidil on 6-month changes in total hair density. Its headline finding was blunt: topical minoxidil 5% was ranked most effective, ahead of topical melatonin, saw palmetto, cetirizine 1%, and topical finasteride. The authors still describe those runners-up as showing potential clinical benefit that warrants further comparative trials, which is researcher language for promising but unproven.

The SinclairDermatology review, led by Rodney Sinclair, fills in the practical picture. Randomised controlled trials show 5% formulations consistently increase hair counts, though results vary between people because of differences in follicular sulfotransferase activity, the enzyme that converts minoxidil to its active form. Response is therefore genuinely individual, and the review describes low-dose oral minoxidil, 0.25 to 5 milligrams, as an option for people who do not respond to the topical version, with hypertrichosis, unwanted hair growth elsewhere, as its most frequent side effect and cardiovascular events uncommon at low doses.

What about hair loss in women?

Female pattern hair loss is where shelf claims do the most damage, because the evidence base is narrower and the marketing is just as loud. The SinclairDermatology review notes androgenetic alopecia affects up to 50 percent of women by age 70, and that topical minoxidil is the only FDA-approved option for women, since finasteride's approval is limited to men. Everything a woman sees marketed beyond topical minoxidil is either prescription off-label use or a cosmetic with no growth evidence attached.

Hypertrichosis deserves specific mention for women weighing oral minoxidil with a prescriber: unwanted facial or body hair is the review's most frequently reported effect of the low-dose oral route. That is a manageable, dose-dependent trade-off rather than a reason to avoid treatment, but it is exactly the kind of concrete, sourced detail marketing leaves out. Sublingual formulations, which the review covers as a newer delivery route, are described as early evidence with possible advantages still to be confirmed.

The other gendered gap is diagnostic. Diffuse shedding in women has several possible drivers besides pattern loss, which is one more reason the reviews route treatment through a dermatologist rather than a serum aisle.

How do popular hair growth claims hold up?

Placed against the same literature, the familiar shelf claims separate into tiers of support:

The pattern to notice is that everything with demonstrated effect is either a drug or works through the same studied pathway, and everything else is earlier-stage.

Timing expectations deserve the same honesty as ingredient rankings. The Gupta meta-analysis measured 6-month changes in total hair density, which is the field's own clock for what counts as a result; a serum judged after two weeks has not been given the timeframe in which even minoxidil demonstrates itself. Buyers comparing products should compare them at the trial clock speed, not the launch-calendar speed, and treat any promise of visible regrowth in days as a signal about marketing rather than biology.

Cost logic follows the same evidence tiers. Prescription minoxidil is generic and inexpensive, while the serum aisle prices innovation claims the evidence does not carry yet. Where a shopper's budget has to choose, the reviewed literature points one direction clearly: the studied active first, and the interesting early-stage option second, if at all.

What can a cosmetic legally claim about hair growth?

Nothing, in the United States, and the distinction matters for reading labels. A product that affects hair growth is a drug, which is exactly why minoxidil appears in FDA-approved treatments rather than in shampoo marketing. Serums and scalp treatments sold as cosmetics can talk about the look and feel of hair, its shine, or its condition when wet, but a claim to regrow hair or reverse thinning moves the product into drug territory.

That regulatory line explains the vagueness readers encounter on packaging. When a serum says it creates a healthy scalp environment, the claim is carefully worded to stay cosmetic. The honest reading, per the two reviews above, is that no over-the-counter cosmetic has been shown to match minoxidil's effect on hair density, and that the FDA-approved options are where the trial data sits.

What should someone noticing shedding actually do?

Both reviews frame treatment as something to individualize, and the steps follow from that:

1. Note when the shedding started and where the thinning concentrates, since pattern differs between types of hair loss.
2. See a dermatologist before buying a shelf of products, because the cause determines the treatment.
3. Ask about minoxidil in its approved topical form, and about oral low-dose options if topical response is poor.
4. Give any real treatment months, since the trials measure change over 6 months, not weeks.
5. Treat marketing terms like natural and clean as labeling, not evidence of efficacy.

One caveat the SinclairDermatology review makes worth repeating: even the best-supported therapy works by slowing loss and regrowing some hair, not by fully restoring a hairline, and results fade if treatment stops. That is the standard every marketing claim should be measured against, and it is a lower bar than most of them imply.

The final honest note is about patience stacked on patience. A dermatologist visit to establish the diagnosis, a trial period measured in months on the studied active, and a follow-up to adjust course is the sequence the evidence actually describes. Against the noise of a category built on ninety-day transformations, that sequence is unglamorous, and it is the only one the reviews recognize.